Entrada Therapeutics, Inc. (TRDA)
Nasdaq: TRDA · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2016
Who owns Entrada Therapeutics, Inc.
As filed with the SECHolders of 5% or more
4
Kush Parmar holds 10.8% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13D/A filed Nov 18, 2025 says.
Directors and officers
11
report now, of 14 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Kush Parmar
SCHEDULE 13D/A · filed Nov 18, 2025 · Common Stock, par value $0.0001 per share
Ansbert Gadicke
SCHEDULE 13D/A · filed Sep 10, 2026 · Common Stock
Roche Finance Ltd
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, $0.0001 par value per share
Blackrock, Inc.
SCHEDULE 13G · filed Feb 4, 2025 · Common Stock
Janus Henderson Group PLC
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock · reported falling below 5%, from 5.6% in May 14, 2025
TCG Crossover GP I, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5% in Nov 25, 2025
T. Rowe Price Associates, Inc.
SCHEDULE 13G/A · filed Nov 14, 2025 · COMMON STOCK · reported falling below 5%, from 6.8% in Aug 14, 2025
What TRDA reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Feb 26, 2026.
Insider tradesForm 4
18sales
1purchases
9sales on a scheduled plan
5people selling
$5.4Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window14 of 34 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Parmar Kush | director | 6 | $3.6M | 0 | 0 | $0 |
| Mpm Bioventures 2018 (B), L.P. | 10% owner | 3 | $1.9M | 0 | 0 | $0 |
| Mpm Bioventures 2018 Gp LLC | 10% owner | 3 | $1.9M | 0 | 0 | $0 |
| 5am Ventures V, L.P. | 10% owner | 1 | $1.8M | 0 | 0 | $0 |
| Mpm Bioventures 2018 LLC | 10% owner | 9 | $1.7M | 0 | 0 | $0 |
| Rocklage Scott M | 10% owner | 4 | $1.2M | 0 | 0 | $0 |
| Mpm Bioventures 2014 (B), L.P. | 10% owner | 3 | $600,000 | 0 | 0 | $0 |
| Mpm Bioventures 2014 Gp LLC | 10% owner | 3 | $600,000 | 0 | 0 | $0 |
| Foley Todd | director | 3 | $500,000 | 0 | 0 | $0 |
| Dowden Nathan J | President & COO | 3 | $400,000 | 3 | 0 | $0 |
| Sethuraman Natarajan | President, Research & Develop. | 1 | $400,000 | 1 | 0 | $0 |
| Wentworth Kory James | Chief Financial Officer | 5 | $400,000 | 5 | 0 | $0 |
| Baker Bros. Advisors (Gp) LLC | 10% owner | 0 | $0 | 0 | 12 | $1.4M |
| Zeiher Bernhardt G | director | 0 | $0 | 0 | 1 | $0 |